XML 28 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
License and Collaboration Agreements (Tables)
 3 Months Ended
Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

 

 

 

 

 

Three months ended March 31,

 

Partner

 

Drug or Drug Candidate

 

2016

 

 

2015

 

AstraZeneca AB

 

MOVANTIKTM (NKTR-118)

and MOVANTIKTM fixed-dose

combination program (NKTR-119)

 

$

28,000

 

 

$

90,000

 

Roche

 

PEGASYS® and MIRCERA®

 

 

1,929

 

 

 

3,212

 

Amgen, Inc.

 

Neulasta®

 

 

1,250

 

 

 

1,250

 

Bayer Healthcare LLC

 

BAY41-6551 (Amikacin Inhale)

 

 

357

 

 

 

810

 

Baxalta Incorporated

 

ADYNOVATETM

 

 

104

 

 

 

109

 

Other

 

 

 

 

2,547

 

 

 

1,359

 

License, collaboration and other

   revenue

 

 

 

$

34,187

 

 

$

96,740